Myeloid-Derived Suppressor Cells Inhibit T Cell Activation through Nitrating LCK

Shan Feng\textsuperscript{a}, Xi Cheng\textsuperscript{a}, Seema Chaudhary\textsuperscript{a}, Liang Cheng\textsuperscript{c}, Xin Lu\textsuperscript{a,b}

\textsuperscript{a}Department of Biological Sciences, Center for Rare and Neglected Diseases, Harper Cancer Research Institute, University of Notre Dame, Notre Dame, IN 46556; \textsuperscript{b}Tumor Microenvironment and Metastasis Program, Indiana University Simon Cancer Center, Indianapolis, IN, 46202; \textsuperscript{c}Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, 46202.

**Background:** Patients with advanced prostate cancer (PCa) benefit from androgen deprivation therapy initially, but often later develop lethal metastatic castration-resistant prostate cancer (mCRPC). Immune checkpoint blockade (ICB) using antibodies against CTLA4 or PD1/PD-L1 generates durable therapeutic responses in a variety of cancer types. However, mCRPC showed overwhelming de novo resistance to ICB. Our recent publications showed that myeloid-derived suppressor cells (MDSCs) are the key player in PCa immune evasion, and targeting MDSCs with multikinase inhibitors or CXCR2 inhibitors could synergize with ICB to elicit potent anti-mCRPC effect in mouse models (\textit{Cancer Discovery, 2016}; \textit{Nature, 2017}). More effective and specific MDSC inhibition relies on deeper mechanistic understanding of MDSCs. One main mechanism for MDSCs to induce T cell tolerance is through secretion of reactive nitrogen species (e.g. peroxynitrite), which nitrates tyrosine residues in proteins involved in T cell function. However, this mechanism remains poorly understood and very few nitrated proteins are known.

**Methods:** We developed a new nitroproteomic approach based on chemical derivation of 3-nitrotyrosine in order to identify novel nitropeptides. The biological models we used for target identification and functional validation are \textit{Pten/p53/Smad4} PCa transgenic model and syngeneic Lewis Lung Carcinoma (LLC) model.

**Results:** We identified that lymphocyte-specific protein tyrosine kinase (LCK), an initiating tyrosine kinase in the T cell receptor signaling cascade, is nitrated at Tyr394 by MDSCs. LCK nitrination inhibited T cell activation, leading to reduced interleukin-2 production and proliferation. In human T cells with defective endogenous LCK, wild type, but not nitrated LCK, rescued IL2 production. We documented elevated 3-nitrotyrosine signals in clinical samples of CRPC. In both the \textit{Pten/p53/Smad4} mCRPC model and LLC model, we showed that ICB therapy (PD1 and CTLA4 antibody cocktail) elicited strong anti-tumor efficacy when combined with a RNS neutralizing agent.

**Conclusions:** We have identified a previously unknown mechanism of T cell inactivation by MDSC-induced protein nitration and illuminated a clinical path hypothesis for combining ICB with RNS-reducing agents in the treatment of mCRPC.

**Conflict of Interest:** We declare no COI.

**Funding Acknowledgements:** ACS Institutional Research Grant IRG-14-195-01 (S. Stack, PI), the Indiana CTSI which is funded in part by grants KL2TR001106 and UL1TR001108 (A. Shekhar, PI) from NIH. XL is a recipient of Indiana CTSI KL2 Young Investigator Award. SF is supported by Walther Cancer Foundation.